Southern Cross Gold Consolidated Ltd's subsidiary has had its mining licence application accepted by Resources Victoria for the Sunday Creek Gold-Antimony Project near Melbourne. This acceptance marks the start of a public review phase, but mining cannot begin until further approvals, including a Mine Work Plan and planning permit, are obtained. The project is significant due to its gold and critical antimony deposits, important for defense and technology sectors. Southern Cross Gold continues exploration and community engagement as it progresses through regulatory steps toward potential mining operations.
Southern Cross Gold's mining licence application is the subject, with this market snapshot from Pluang for context. Of 38 Basic Materials-sector US stocks priced on Pluang, 6 rose and 30 fell. AngloGold Ashanti Limited (AU) traded at USD 99.86 with a 1-day change of -4.53%, Gold Fields Limited (GFI) at USD 41.07 down 4.40%, and Harmony Gold Mining Co. (HMY) at USD 19.02 down 4.04%. Data is as of Sep 23, 2026 16:51 WIB.
A Snap insider has sold 20,000 shares as the company's stock has declined by 27% over the last year. This insider sale may signal concerns about the stock's near-term prospects or a personal decision to liquidate holdings. Investors should watch for ...
Analyst Daniel Sparks projects Sandisk's stock price to rise from about $1,790 to the low $2,000s by 2030. This growth forecast suggests the stock will not outperform the broader market during this period. Investors should consider this moderate outl...
In September 2026, five monthly dividend stocks popular among Boomer investors demonstrated reliable income streams and growth. Realty Income, Agree Realty, STAG Industrial, Main Street Capital, and Gladstone Investment each either raised or maintain...
PONS crypto rose 11% recently, showing signs of building momentum with a potential 40% gain if it reaches $1. However, the altcoin faces challenges due to a significant drop in the Pons app's daily revenue, falling from $11M to $2M, which funds 80% o...
Cardiol Therapeutics has achieved its original enrollment target of 110 patients early in its Phase III MAVERIC trial for CardiolRx™, a drug aimed at reducing recurrent pericarditis risk. Due to fewer-than-expected recurrences observed in a blinded r...
